Vvax 001

Drug Profile

Vvax 001

Alternative Names: rSFVeE6,7; Semliki Forest Virus Based Cancer Vaccine; SFVeE6,7; Vvax-001

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViciniVax
  • Developer University of Groningen
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia

Most Recent Events

  • 13 Jan 2017 Phase-I clinical trials in Cervical intraepithelial neoplasia in Netherlands (IM) (NCT03141463)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cervical-intraepithelial-neoplasia in Netherlands (IM, Injection)
  • 26 Aug 2013 Research programme: cervical cancer vaccine - ViciniVax is available for licensing as of 26 Aug 2013. http://www.vicinivax.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top